Spencer Ryan has filed 48 insider transactions across 2 companies since February 2024.
Most recent transaction: a transaction of 379620 shares of DYNAVAX TECHNOLOGIES CORP ($DVAX) on February 10, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | U | Common Stock | 379620 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.28% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | D | Restricted Stock Units | 90667 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.07% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | D | Restricted Stock Units | 55000 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.04% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | D | Stock Option (Right to Buy) | 225000 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.16% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | D | Stock Option (Right to Buy) | 231000 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.17% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | D | Stock Option (Right to Buy) | 280000 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.21% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | D | Stock Option (Right to Buy) | 350000 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.26% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | D | Stock Option (Right to Buy) | 250000 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.18% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | D | Stock Option (Right to Buy) | 130000 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.10% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | D | Stock Option (Right to Buy) | 400000 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.29% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | D | Stock Option (Right to Buy) | 50000 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.04% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | D | Common Stock - Performance Stock Units | 136000 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.10% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | A | Common Stock - Performance Stock Units | 136000 | $0.00 | 136,000.0000 | 136,468,000 | 9999.99% | 0.10% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | D | Common Stock - Performance Stock Units | 165000 | $0.00 | 0.0000 | 136,468,000 | 100.00% | 0.12% |
| Feb. 10, 2026 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | A | Common Stock - Performance Stock Units | 165000 | $0.00 | 165,000.0000 | 136,468,000 | 9999.99% | 0.12% |
| Jan. 7, 2026 | Cidara Therapeutics, Inc. | $CDTX | Spencer Ryan | Director | D | Stock Option (right to buy) | 2125 | $0.00 | 0.0000 | 31,439,371 | 100.00% | 0.01% |
| Jan. 7, 2026 | Cidara Therapeutics, Inc. | $CDTX | Spencer Ryan | Director | D | Stock Option (right to buy) | 11100 | $0.00 | 0.0000 | 31,439,371 | 100.00% | 0.04% |
| Jan. 7, 2026 | Cidara Therapeutics, Inc. | $CDTX | Spencer Ryan | Director | D | Stock Option (right to buy) | 4250 | $0.00 | 0.0000 | 31,439,371 | 100.00% | 0.01% |
| Dec. 23, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | A | Common Stock | 156250 | $0.00 | 417,455.0000 | 136,468,000 | 59.82% | 0.11% |
| Dec. 23, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | M | Common Stock | 55000 | $0.00 | 472,455.0000 | 136,468,000 | 13.18% | 0.04% |
| Dec. 23, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | M | Common Stock | 45333 | $0.00 | 517,788.0000 | 136,468,000 | 9.60% | 0.03% |
| Dec. 24, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | F | Common Stock | 138168 | $15.38 | 379,620.0000 | 136,468,000 | 26.68% | 0.10% |
| Dec. 23, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | M | Restricted Stock Unit | 55000 | $0.00 | 55,000.0000 | 136,468,000 | 50.00% | 0.04% |
| Dec. 23, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | M | Restricted Stock Unit | 45333 | $0.00 | 90,667.0000 | 136,468,000 | 33.33% | 0.03% |
| June 18, 2025 | Cidara Therapeutics, Inc. | $CDTX | Spencer Ryan | Director | A | Stock Option (right to buy) | 11100 | $0.00 | 11,100.0000 | 10,953,490 | 9999.99% | 0.10% |
| Feb. 18, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | M | Common Stock | 55000 | $0.00 | 297,261.0000 | 133,344,000 | 22.70% | 0.04% |
| Feb. 18, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | M | Restricted Stock Unit | 55000 | $0.00 | 110,000.0000 | 133,344,000 | 33.33% | 0.04% |
| Feb. 18, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | F | Common Stock | 36528 | $12.93 | 260,733.0000 | 133,344,000 | 12.29% | 0.03% |
| Feb. 13, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | A | Restricted Stock Unit | 136000 | $0.00 | 136,000.0000 | 133,344,000 | 9999.99% | 0.10% |
| Feb. 13, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | A | Stock Option (Right to Buy) | 225000 | $0.00 | 225,000.0000 | 133,344,000 | 9999.99% | 0.17% |
| Feb. 13, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | M | Restricted Stock Unit | 62500 | $0.00 | 0.0000 | 133,344,000 | 100.00% | 0.05% |
| Feb. 13, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | A | Restricted Stock Unit | 62500 | $0.00 | 62,500.0000 | 133,344,000 | 9999.99% | 0.05% |
| Feb. 13, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | F | Common Stock | 31694 | $12.69 | 242,261.0000 | 133,344,000 | 11.57% | 0.02% |
| Feb. 13, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | M | Common Stock | 62500 | $0.00 | 273,522.0000 | 133,344,000 | 29.62% | 0.05% |
| Feb. 10, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | F | Common Stock | 11209 | $13.20 | 211,022.0000 | 133,344,000 | 5.04% | 0.01% |
| Feb. 10, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | M | Restricted Stock Unit | 20833 | $0.00 | 0.0000 | 133,344,000 | 100.00% | 0.02% |
| Feb. 10, 2025 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | M | Common Stock | 20833 | $0.00 | 222,231.0000 | 133,344,000 | 10.34% | 0.02% |
| July 18, 2024 | Cidara Therapeutics, Inc. | $CDTX | Spencer Ryan | Director | A | Stock Option (right to buy) | 2125 | $0.00 | 2,125.0000 | 0 | 9999.99% | 0.00% |
| April 26, 2024 | Cidara Therapeutics, Inc. | $CDTX | Spencer Ryan | Director | A | Stock Option (right to buy) | 4250 | $0.00 | 4,250.0000 | 0 | 9999.99% | 0.00% |
| Feb. 15, 2024 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | A | Common Stock | 402 | $9.45 | 201,030.0000 | 128,733,000 | 0.20% | 0.00% |
| Feb. 15, 2024 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | A | Stock Options (Right to Buy) | 231000 | $0.00 | 231,000.0000 | 128,733,000 | 9999.99% | 0.18% |
| Feb. 15, 2024 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | A | Restricted Stock Unit | 165000 | $0.00 | 165,000.0000 | 128,733,000 | 9999.99% | 0.13% |
| Feb. 12, 2024 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | F | Common Stock | 11684 | $12.82 | 200,628.0000 | 128,733,000 | 5.50% | 0.01% |
| Feb. 10, 2024 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | M | Restricted Stock Unit | 20833 | $0.00 | 20,833.0000 | 128,733,000 | 50.00% | 0.02% |
| Feb. 10, 2024 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | M | Common Stock | 20833 | $0.00 | 212,312.0000 | 128,733,000 | 10.88% | 0.02% |
| Feb. 4, 2024 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | M | Common Stock | 29750 | $0.00 | 208,608.0000 | 128,733,000 | 16.63% | 0.02% |
| Feb. 5, 2024 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | F | Common Stock | 17129 | $12.79 | 191,479.0000 | 128,733,000 | 8.21% | 0.01% |
| Feb. 4, 2024 | DYNAVAX TECHNOLOGIES CORP | $DVAX | Spencer Ryan | CEO and Director | M | Restricted Stock Unit | 29750 | $0.00 | 0.0000 | 128,733,000 | 100.00% | 0.02% |